Cordlife Group Limited (CLIFF)
USD 0.1
(-20.0%)
USD 0.1
(-20.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.5 Million SGD | 58.1% |
| 2022 | 2.21 Million USD | 0.83% |
| 2021 | 2.19 Million SGD | -62.03% |
| 2020 | 5.79 Million SGD | 14.67% |
| 2019 | 5.04 Million SGD | 9.66% |
| 2018 | 4.6 Million SGD | -15.3% |
| 2017 | 5.43 Million SGD | -37.73% |
| 2016 | 8.73 Million SGD | -88.84% |
| 2015 | 78.26 Million SGD | -18.5% |
| 2014 | 96.02 Million SGD | 647.31% |
| 2013 | 12.85 Million SGD | 107.36% |
| 2012 | 6.19 Million SGD | 141.13% |
| 2011 | 2.57 Million SGD | 3679.41% |
| 2010 | 68 Thousand SGD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 2.63 Million SGD | 59.74% |
| 2023 Q2 | 3.22 Million USD | 22.22% |
| 2023 Q4 | 2.65 Million USD | 56.9% |
| 2023 FY | 3.5 Million SGD | 58.1% |
| 2023 Q3 | 1.69 Million SGD | -47.54% |
| 2022 Q1 | 813 Thousand SGD | -72.6% |
| 2022 FY | 2.21 Million USD | 0.83% |
| 2022 Q4 | 1.65 Million USD | 62.29% |
| 2022 Q3 | 1.01 Million SGD | -38.84% |
| 2022 Q2 | 1.66 Million SGD | 104.73% |
| 2021 Q1 | 1.42 Million SGD | -81.39% |
| 2021 Q3 | 843 Thousand SGD | -65.56% |
| 2021 Q4 | 2.96 Million SGD | 251.96% |
| 2021 FY | 2.19 Million SGD | -62.03% |
| 2021 Q2 | 2.44 Million SGD | 71.91% |
| 2020 Q2 | 8.5 Million SGD | 62.84% |
| 2020 Q3 | 6.07 Million SGD | -28.55% |
| 2020 Q4 | 7.65 Million SGD | 26.02% |
| 2020 FY | 5.79 Million SGD | 14.67% |
| 2020 Q1 | 5.22 Million SGD | -23.12% |
| 2019 Q4 | 6.79 Million SGD | 55.16% |
| 2019 Q1 | 4.52 Million SGD | -1.67% |
| 2019 FY | 5.04 Million SGD | 9.66% |
| 2019 Q2 | 4.45 Million SGD | -1.68% |
| 2019 Q3 | 4.37 Million SGD | -1.71% |
| 2018 Q2 | 5.43 Million SGD | -18.66% |
| 2018 FY | 4.6 Million SGD | -15.3% |
| 2018 Q4 | 4.6 Million SGD | -14.1% |
| 2018 Q3 | 5.36 Million SGD | -1.4% |
| 2018 Q1 | 6.68 Million SGD | -1.04% |
| 2017 Q4 | 6.75 Million SGD | -9.96% |
| 2017 FY | 5.43 Million SGD | -37.73% |
| 2017 Q3 | 7.5 Million SGD | -14.09% |
| 2017 Q2 | 8.73 Million SGD | -0.81% |
| 2017 Q1 | 8.8 Million SGD | -0.82% |
| 2016 Q4 | 8.87 Million SGD | -88.51% |
| 2016 FY | 8.73 Million SGD | -88.84% |
| 2016 Q3 | 77.2 Million SGD | -1.35% |
| 2016 Q2 | 78.26 Million SGD | 0.1% |
| 2016 Q1 | 78.19 Million SGD | -5.55% |
| 2015 FY | 78.26 Million SGD | -18.5% |
| 2015 Q4 | 82.78 Million SGD | -36.07% |
| 2015 Q3 | 129.49 Million SGD | 0.14% |
| 2015 Q2 | 129.3 Million SGD | 0.46% |
| 2015 Q1 | 128.71 Million SGD | -0.06% |
| 2014 Q1 | 12.91 Million SGD | -0.49% |
| 2014 Q4 | 128.79 Million SGD | 909.38% |
| 2014 Q3 | 12.76 Million SGD | -0.7% |
| 2014 Q2 | 12.85 Million SGD | -0.48% |
| 2014 FY | 96.02 Million SGD | 647.31% |
| 2013 Q3 | 6.13 Million SGD | -0.98% |
| 2013 Q4 | 12.97 Million SGD | 111.46% |
| 2013 FY | 12.85 Million SGD | 107.36% |
| 2013 Q1 | 5.45 Million SGD | -1.07% |
| 2013 Q2 | 6.19 Million SGD | 13.71% |
| 2012 Q1 | 1.98 Million SGD | 0.0% |
| 2012 FY | 6.19 Million SGD | 141.13% |
| 2012 Q2 | 2.57 Million SGD | 29.21% |
| 2012 Q4 | 5.5 Million SGD | -1.08% |
| 2012 Q3 | 5.56 Million SGD | 116.69% |
| 2011 Q2 | 68 Thousand SGD | 0.0% |
| 2011 FY | 2.57 Million SGD | 3679.41% |
| 2010 FY | 68 Thousand SGD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | -56.473% |
| Arrayit Corporation | 1.07 Million USD | -225.089% |
| Atlantic International Corp. | 2.93 Million USD | -19.605% |
| Biocept, Inc. | 12.1 Million USD | 71.055% |
| Bioqual, Inc. | 3.58 Million USD | 2.286% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -4726.893% |
| DermTech, Inc. | 54.39 Million USD | 93.556% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 471.86 Million USD | 99.257% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | 27.492% |
| iMD Companies, Inc. | 1.12 Million USD | -212.905% |
| IDenta Corp. | 789.14 Thousand USD | -344.151% |
| Interpace Biosciences, Inc. | 11.19 Million USD | 68.683% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -7894.07% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | 56.432% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | 8.387% |
| NovelStem International Corp. | 3.57 Million USD | 1.947% |
| Optigenex Inc. | 8.94 Million USD | 60.797% |
| PharmChem, Inc. | 77.35 Thousand USD | -4431.175% |
| Proteome Sciences plc | 17.15 Million USD | 79.567% |
| Response Genetics, Inc | 6.37 Million USD | 45.002% |
| Rennova Health, Inc. | 15.32 Million USD | 77.135% |
| RushNet, Inc. | 4.82 Million USD | 27.329% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -1592.959% |
| Stella Diagnostics Inc. | 6.2 Million USD | 43.474% |
| StageZero Life Sciences Ltd. | 1.8 Million USD | -94.713% |
| Todos Medical Ltd. | 38.34 Million USD | 90.86% |